IP Library › Granted Patent US 12,708,668
Granted Patent B2
US 12,708,668 · App. 17/755,573 · Granted Aug 18, 2026

Stable aqueous anti-TFPI antibody formulation

Inventors: Thomas Joseph Crowley (Wilmington, MA); Robert Lee Dufield (Overland Park, KS); Jennifer Juneau (Sterling, MA)
Assignee: Pfizer Inc.
A61K39/39591A61K47/12A61K47/22A61K47/26A61P7/04C07K16/38A61K2039/54C07K2317/32C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,708,668
App. No.
17/755,573
Filed
May 2, 2022
Granted
Aug 18, 2026
Kind
B2
Examiner
KIM, YUNSOO
Art Unit
1641
USPC
424/139.1
Abstract

The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by an aqueous formulation of an anti-Tissue Factor Pathway Inhibitor (TFPI) antibody.

Claims (20)

1 . A stable pharmaceutical formulation consisting of: about 100 mg/mL to about 150 mg/mL of an antibody that specifically binds to an epitope in Kunitz Domain 2 (K2) of Tissue Factor Pathway Inhibitor (TFPI), about 20 mM histidine buffer, about 85 mg/mL sucrose, about 0.2 mg/mL polysorbate 80 and about 0.05 mg/mL disodium edetate dihydrate (EDTA), wherein the formulation has a pH at about 5.8, wherein the histidine buffer comprises L-histidine, L-histidine monohydrochloride or a mixture thereof, and wherein the antibody comprises:

(i) a heavy chain variable region (VH) comprising: (a) a VH complementarity determining region one (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 13; (b) a VH complementarity determining region two (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 14; and (c) a VH complementarity determining region three (CDR-H3) comprising the amino acid sequence of SEQ ID NO: 15, and

(ii) a light chain variable region (VL) comprising: (a) a VL complementarity determining region one (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 8; (b) a VL complementarity determining region two (CDR-L2) comprising the amino acid sequence of SEQ ID NO: 9; and (c) a VL complementarity determining region three (CDR-L3) comprising the amino acid sequence of SEQ ID NO: 10.

2 . The stable pharmaceutical formulation of claim 1 , wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 18, and a VL comprising the amino acid sequence of SEQ ID NO: 11.

3 . The stable pharmaceutical formulation of claim 1 , wherein the antibody comprises a VH sequence encoded by the insert present in the plasmid deposited under ATCC Accession No. PTA-122329, and a VL sequence encoded by the insert present in the plasmid deposited under ATCC Accession No. PTA-122328.

4 . The stable pharmaceutical formulation of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19, and a light chain comprising the amino acid sequence of SEQ ID NO: 12.

5 . The stable pharmaceutical formulation of claim 1 , wherein the concentration of the antibody is about 100 mg/mL, about 115 mg/mL or about 150 mg/mL.

6 . A stable pharmaceutical formulation consisting of: 150 mg/mL of an antibody that specifically binds to an epitope in Kunitz Domain 2 (K2) of Tissue Factor Pathway Inhibitor (TFPI), 20 mM histidine buffer, 85 mg/mL sucrose, 0.2 mg/mL polysorbate 80, and 0.05 mg/mL disodium edetate dihydrate, wherein the histidine buffer comprises L-histidine, L-histidine monohydrochloride or a mixture thereof, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 18, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 11, and wherein the formulation has a pH of 5.8.

7 . A stable pharmaceutical formulation consisting of: 150 mg/mL of an antibody that specifically binds to an epitope in Kunitz Domain 2 (K2) of Tissue Factor Pathway Inhibitor (TFPI), 20 mM histidine buffer, 85 mg/mL sucrose, 0.2 mg/mL polysorbate 80, and 0.05 mg/mL disodium edetate dihydrate, wherein the histidine buffer comprises L-histidine, L-histidine monohydrochloride or a mixture thereof, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19, and a light chain comprising the amino acid sequence of SEQ ID NO: 12, and wherein the formulation has a pH of 5.8.

8 . A stable pharmaceutical formulation consisting of: 150 mg/mL of an antibody that specifically binds to an epitope in Kunitz Domain 2 (K2) of Tissue Factor Pathway Inhibitor (TFPI), 20 mM histidine buffer, 85 mg/mL sucrose, 0.2 mg/mL polysorbate 80, and 0.05 mg/mL disodium edetate dihydrate, wherein the histidine buffer comprises L-histidine, L-histidine monohydrochloride or a mixture thereof, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 17, and a light chain comprising the amino acid sequence of SEQ ID NO: 12, and wherein the formulation has a pH of 5.8.

9 . The stable pharmaceutical formulation of claim 1 , wherein the formulation has a shelf life of at least about 24 months at 5±3° C.

10 . The stable pharmaceutical formulation of claim 1 , wherein the formulation has less than about 7% high molecular mass species (HMMS) at 40° C./75% relative humidity (RH) for up to 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months, optionally as measured by size exclusion high performance liquid chromatography (SE-HPLC).

11 . The stable pharmaceutical formulation of claim 1 , wherein the formulation has less than about 3% HMMS at 40° C. for up to 1 month, 2 months, or 3 months, optionally as measured by SE-HPLC.

12 . The stable pharmaceutical formulation of claim 1 , wherein the formulation has less than about 2% HMMS at 40° C. for up to 1 month, optionally as measured by SE-HPLC.

13 . A method of shortening bleeding time, comprising administering to a subject in need thereof a therapeutically effective amount of the stable pharmaceutical formulation of claim 1 .

14 . A method of treating a deficiency in blood coagulation or a bleeding disorder, comprising administering to a subject in need thereof a therapeutically effective amount of the stable pharmaceutical formulation of claim 1 .

15 . A method of treating hemophilia A, B or C, comprising administering to a subject in need thereof a therapeutically effective amount of the stable pharmaceutical formulation of claim 1 .

16 . A method of treating von Willebrand Disease (vWD), comprising administering to a subject in need thereof a therapeutically effective amount of the stable pharmaceutical formulation of claim 1 .

17 . A method for reducing the activity of TFPI, comprising administering to a subject in need thereof a therapeutically effective amount of the stable pharmaceutical formulation of claim 1 .

18 . The method of claim 13 , wherein the stable pharmaceutical formulation is administered to the subject subcutaneously or intravenously.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →
Continuity (3)
Provisional Application 63081409 · Sep 22, 2020
Provisional Application 62934781 · Nov 13, 2019
Related Publication 20230035617A1 · Feb 2, 2023
References Cited (136)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 5807715A · Morrison et al. · 1998 [cited by applicant]
US 5866692A · Shitara et al. · 1999 [cited by applicant]
US 5997867A · Waldmann et al. · 1999 [cited by applicant]
US 6054297A · Carter et al. · 2000 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 6180377B1 · Morgan et al. · 2001 [cited by applicant]
US 6210671B1 · Co et al. · 2001 [cited by applicant]
US 6331415B1 · Cabilly et al. · 2001 [cited by applicant]
US 6350861B1 · Co et al. · 2002 [cited by applicant]
US 8361469B2 · Hilden et al. · 2013 [cited by applicant]
US 8481030B2 · Wang et al. · 2013 [cited by applicant]
US 10550200B2 · Pittman et al. · 2020 [cited by applicant]
US 10875929B2 · Pittman et al. · 2020 [cited by applicant]
US 10894083B2 · Ingram et al. · 2021 [cited by applicant]
US 11634504B2 · Pittman et al. · 2023 [cited by applicant]
US 20050276823A1 · Cini · 2005 [cited by examiner]
US 20060088523A1 · Andya · 2006 [cited by examiner]
US 20090238820A1 · Allan et al. · 2009 [cited by applicant]
US 20110268745A1 · Hilden et al. · 2011 [cited by applicant]
US 20110318356A1 · Hilden et al. · 2011 [cited by applicant]
US 20120028901A1 · Dockal et al. · 2012 [cited by applicant]
US 20120108796A1 · Wang et al. · 2012 [cited by applicant]
US 20120269817A1 · Wang et al. · 2012 [cited by applicant]
US 20130136733A1 · Parshad et al. · 2013 [cited by applicant]
US 20130251721A1 · Hilden et al. · 2013 [cited by applicant]
US 20130251722A1 · Hilden et al. · 2013 [cited by applicant]
US 20140065159A1 · Ma et al. · 2014 [cited by applicant]
US 20140294832A1 · Wang et al. · 2014 [cited by applicant]
US 20170073428A1 · Pittman et al. · 2017 [cited by applicant]
US 20170360929A1 · Sinha et al. · 2017 [cited by applicant]
US 20180000933A1 · Ingram et al. · 2018 [cited by applicant]
US 20180055940A1 · Ma et al. · 2018 [cited by applicant]
AU 2014200227A1 · 2014 [cited by applicant]
EP 0519596 · 1992 [cited by applicant]
EP 2746294A2 · 2014 [cited by applicant]
EP 3345615A1 · 2018 [cited by applicant]
RU 2562114C2 · 2015 [cited by applicant]
WO 1999058572 · 1999 [cited by applicant]
WO 2001027160 · 2001 [cited by applicant]
WO 2006096491 · 2006 [cited by applicant]
WO 2008147196A3 · 2009 [cited by applicant]
WO 2010017196 · 2010 [cited by applicant]
WO 2010032220 · 2010 [cited by applicant]
WO 2010072687 · 2010 [cited by applicant]
WO 2010072691 · 2010 [cited by applicant]
WO 2011104381 · 2011 [cited by applicant]
WO 2011109452 · 2011 [cited by applicant]
WO 2011147921A1 · 2011 [cited by applicant]
WO 2012001087 · 2012 [cited by applicant]
WO 2012135671A2 · 2012 [cited by applicant]
WO 2013023251A1 · 2013 [cited by applicant]
WO 2013148248A1 · 2013 [cited by applicant]
WO 2013186719 · 2013 [cited by applicant]
WO 2014036071A1 · 2014 [cited by applicant]
WO 2014144689A1 · 2014 [cited by applicant]
WO 2014140240 · 2014 [cited by applicant]
WO 2014144577 · 2014 [cited by applicant]
WO 2015007880 · 2015 [cited by applicant]
WO 2016084912A1 · 2016 [cited by applicant]
WO 2016120753 · 2016 [cited by applicant]
WO 2016137108A1 · 2016 [cited by applicant]
WO 2017029583 · 2017 [cited by applicant]
WO 2017055966A1 · 2017 [cited by applicant]
WO 2020075083 · 2020 [cited by applicant]
WO 2021094917A1 · 2021 [cited by applicant]
Brown et al. Cancer Res. 47: 3577-3583 1987. [cited by applicant]
Caceci et al. 1984, Byte 9: 340-362). [cited by applicant]
Chothia and Lesk, J Mol Biol 196(4): 901-917, 1987. [cited by applicant]
Chothia et al., 1989, Nature, 342: 877-83. [cited by applicant]
Daugherty et al., Nucl. Acids Res. 19: 2471-2476, 1991. [cited by applicant]
International Search Report; PCT/IB2020/060571; 22pages; mailed: Feb. 4, 2021. [cited by applicant]
Johnson & Wu, 2000, Nucleic Acids Res., 28: 214-8. [cited by applicant]
Jones et al. Nature 321: 522-525 1986. [cited by applicant]
Kohler and Milstein, 1975, Nature 256:495. [cited by applicant]
Lobuglio et al. Proc. Nat. Acad. Sci. USA 86: 4220-4224, 1989. [cited by applicant]
MacCallum et al., 1996, J. Mol. Biol., 5:732-45. [cited by applicant]
Makabe et al., 2008, Journal of Biological Chemistry, 283:1156-1166. [cited by applicant]
Martin et al., 1989, Proc Natl Acad Sci (USA), 86:9268-9272. [cited by applicant]
McCafferty et al., 1990, Nature 348:552-554. [cited by applicant]
Riechmann et al. Nature 332: 323-327, 1988. [cited by applicant]
Samudrala et al., 1999, Proteins, Structure, Function and Genetics Suppl., 3:194-198. [cited by applicant]
Shaw et al. J Immunol. 138: 4534-4538, 1987. [cited by applicant]
Verhoeyen et al. Science 239: 1534-1536, 1988. [cited by applicant]
Wang, International J. of Pharmaceutics; vol. 185; No. 2; 1999; pp. 129-188. [cited by applicant]
Wang et al., J. Pharm Sci. 96:1-26, 2007. [cited by applicant]
Winter et al. Nature 349: 293-299, 1991. [cited by applicant]
Wong & Lohman, Proc. Natl. Acad. Sci. USA 90: 5428-5432, 1993. [cited by applicant]
Abumiya, T., et al., “An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma,” The Journal of Biochemi… [cited by applicant]
Agerso, H., et al., “Pharmacokinetics an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration,” European Journal of Ph… [cited by applicant]
Anonymous: “Anti-Human TFPI (KUNITZ-2),” XP55313565, Retrieved from the Internet: URL:http://www.sanquin.nl/repository/reagentia/ifu/MW1845.pdf; 2008. [cited by applicant]
Beringer et al., Remington's Pharmaceutical Sciences, Mack Pub., 21st Edition, 2005, pp. 1072-1076. [cited by applicant]
Boerner, P., et al., “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes,” The Journal of Immunology, 1991, 147 (1):86-95. [cited by applicant]
Brovc, E.A., et al., “Protein formulations containing polysorbates: Are metal chelators needed at all?” Antioxidants, 2020, 9(5):441, 13 pp. [cited by applicant]
Cardinal, M., et al., “A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers,” Journal of Thrombosis… [cited by applicant]
Chowdary, P., et al., “Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial,” Journal of Thrombosis and Haemostasis, 2015… [cited by applicant]
Eichler, H., et al., “Concizumab (anti-TFPI) Exposure-Response Modeling in Patients with Hemophilia A,” Blood, 2017, 130(Suppl 1):3672. [cited by applicant]
Fizika belka: Kurs lektcii′s tcvetny′mi i stereoskopicheskimi illiustratciiami i zadachami: uchebnoe posobie / A.V. Finkel′shtei′n, O.B. Ptitcy′n,—4-e izdanie, ispr. i dop.—M.: KDU, 2012, p. 23 (English Translation). [cited by applicant]
Gennaro, AR., Remington's Pharmaceutical Sciences (2000) 20th Ed., LiPPincott Williams & Wilkins, Baltimore, MD, Cover and Table of Contents. [cited by applicant]
Hansen, L., et al., “Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor”, Thrombosis Research, 2013, 133(3):464… [cited by applicant]
Hilden, I., et al., “Hemostatic Effect of a Monoclonal Antibody mAb 2021 Blocking the Interaction Between FXa and TFPI in a Rabbit Hemophilia Model,” Blood, 2012, 119(24):5871-5878. [cited by applicant]
Holliger, P., and Hudson, P.J., “Engineered antibody fragments and the rise of single domains,” Nature Biotechnology, 2005, 23(9):1126-1136. [cited by applicant]
International Preliminary Report on Patentability issued in PCT/IB2020/060571; mailed on May 27, 2022; 12 pp. [cited by applicant]
Janeway, C., and Travers, P., Immunobiology: The Immune System in Health and Disease, 3rd edition, 1999, Garland Publishing, Inc., 3:1-3:11. [cited by applicant]
Korte, W., et al., “The Potential Close Future of Hemophilia Treatment—Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody,” Transfusion Medicine and Hemotherapy,… [cited by applicant]
Marks, J.D., et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage,” Journal of Molecular Biology, 1991, 222, 581-597. [cited by applicant]
Massimo F. et al., “Non-factor replacement therapy for haemophilia: a current update,” Blood Transfusion = Transfusion Del Sangue 09, 2018, 16:5, 457-461. [cited by applicant]
Petersen, L.C., “Hemostatic Properties of a TFPI Antibody,” Thrombosis Research, 2012, 129 (Suppl. 2):S44-S45. [cited by applicant]
Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Sciences USA, 1982, 79(6):1979-83. [cited by applicant]
Sheets, M. D., et al., “Efficient Construction of a Large Nonimmune Phage Antibody Library: The Production of High-Affinity Human Single-Chain Antibodies to Protein Antigens,” Proceedings of the National Academy of Scie… [cited by applicant]
Sprecher, C.A., et al., “Molecular Cloning, Expression, and Partial Characterization of a Second Human Tissue-Factor-Pathway Inhibitor,” Proceedings National Academy of Science, 1994, 91:3353-3357. [cited by applicant]
Vaughan, T. J., et al., “Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library,” Nature, 1996, 14:309-314. [cited by applicant]
Ward, S.E., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from [cited by applicant]
Winckers, K., et al., “Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study,” Journal of Thrombosis and Haemostasis, 2011, 9(11):2243-2… [cited by applicant]
Yarilin, A.A., “Osnovy immunologii,” M.: Meditsina, 1999, pp. 169-179 (English Translation). [cited by applicant]
Zhou, S., et al., “Comparative evaluation of disodium edetate and diethylenetriaminepentaacetic acid as iron chelators to prevent metal-catalyzed destabilization of a therapeutic monoclonal antibody,” Journal of the Ame… [cited by applicant]
Alhemo (concizumab-mtci), U.S. Prescribing Information, Jul. 2025, pp. 1-12, Retrieved on Sep. 5, 2025, https://www.novo-pi.com/alhemo.pdf. [cited by applicant]
Hemlibra (emicizumab-kxwh), U.S. Prescribing Information, Jul. 2025, pp. 1-26, Retrieved Sep. 5, 2025, https://www.gene.com/download/pdf/hemlibra_prescribing.pdf. [cited by applicant]
Hympavzi (marstacimab-hncq), U.S. Prescribing Information, Oct. 2024, pp. 1-30, Retrieved Sep. 5, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=20916. [cited by applicant]
Matino, D., et al., “Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial,” 2023, Blood, 142:285-287. [cited by applicant]
Nayak, S., et al., “A Fixed (Weight-independent) Subcutaneous Once-Weekly Dose for Marstacimab, an Anti-TFPI Monoclonal Antibody for the Prophylactic Treatment of Hemophilia A and B,” 2024, Blood, 144:1215. [cited by applicant]
Nayak, S., et al., “A Fixed (Weight-independent) Subcutaneous Once-Weekly Dose for Marstacimab, and Anti-TPFI Antibody for the Prophylactic Treatment of Hemophilia A and B,” American Society of Hematology (ASH), Annual … [cited by applicant]
Nayak, S., et al., “Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers,” 2015, CPT Pharmacometrics System Pharmacology, 4:396-405. [cited by applicant]
Van De Weert, M., and Randolph, T.W., “Physical Instability of Peptides and Proteins.” In Pharmaceutical Formulation Development of Peptides and Proteins, 2nd edition, eds., Hovgaard, L., et al., CRC Press, 2nd ed., 201… [cited by applicant]
Goswami, S., et al., “Developments and Challenges for mAb-Based Therapeutics” Antibodies, 2013, 2:452-500. [cited by applicant]